## **RSC Advances**



## **PAPER**

View Article Online
View Journal | View Issue



Cite this: RSC Adv., 2020, 10, 25999

# Pseudo-ginsengenin DQ ameliorated aconitineinduced arrhythmias by influencing Ca<sup>2+</sup> and K<sup>+</sup> currents in ventricular myocytes†

Lifang Jin, ab Cuizhu Wang, Jinping Liu, a Pingya Li, Jing Li, Xiaoli Cuic and Yi Wang \*\*

Pseudo-ginsengenin DQ (PDQ) is the product of the oxidative cyclization of protopanaxadiol. PDQ exhibits various bioactivities, including reversal of multidrug resistance in cancer, renal protective effects against acute nephrotoxicity and attenuating myocardial ischemia injury induced by isoproterenol or ligation of coronary arterials, but its effect on arrhythmias has not been clear until now. Because of the complicated effects of ginseng on the cardiovascular system, it is necessary to investigate whether PDQ affects arrhythmias, which are always concomitant with other cardiac diseases. Aconitine was used to induce arrhythmia *in vivo*. To understand its electrophysiological fundamental, whole-cell patch-clamp was used to record the L-type calcium current ( $I_{Ca,L}$ ) and potassium currents ( $I_K$  and  $I_{K1}$ ) in the ventricular myocytes in rats. Oral administration of PDQ exerted obvious antiarrhythmic effects, as indicated by the decreased incidence rate, lower number of occurrences, and shorter duration time of ventricular tachycardia and ventricular tachycardia, decreased mortality rate and increased survival time.  $I_{Ca,L}$  and  $I_K$  were inhibited by PDQ treatment while  $I_{K1}$  was not affected. To conclude, PDQ may have an antiarrhythmia effect through inhibiting  $I_{Ca,L}$  and  $I_K$ .

Received 21st February 2020 Accepted 8th June 2020

DOI: 10.1039/d0ra01683g

rsc.li/rsc-advances

## 1. Introduction

Arrhythmias, as major types of heart malfunctions, often occur due to production or conduction of cardiac rhythm, which can cause hemodynamic changes, cardiac dilation, and ventricular filling pressure overload.1-5 Ginseng, the root of Panax ginseng Mayer, has been widely used to treat cardiovascular diseases in several countries. 6-9 Ginsenosides are the main active ingredients, which were reported to have anti-arrhythmic effect. 10 The main type of ginsenosides in ginseng is the dammarane type in the ginseng, while in the American ginseng it is the ocotilloltype (20,24-epoxyside)saponin. Ocotillol-type ginsenosides were reported to have multiple biological activities such as neuroprotective, anti-inflammatory, anti-bacterial, and antitumor effects.11-14 Therefore, some ocotillol-type saponins have been semi-synthesized by modifying dammarane-type saponins. Among them, Pseudo-ginsengenin DQ (PDQ) can be prepared by the oxidation and cyclization of the side-chain of protopanaxadiol with a yield of 75% (ZL 200510016774.4).15

PDQ has not only shown chemo-reversal ability in cancer via

overcoming multidrug resistance,16 but also renal protective

Aconitine is a fatal toxin isolated from aconitum plant, which is the commonly used chemical to induce different kinds of arrhythmias, including ventricular premature beat (VP), ventricular tachycardia (VT), ventricular fibrillation (VF) and cardiac arrest, *etc.*<sup>20</sup> Its electrophysiological mechanism involves mainly in multiple ion channels in myocyte membrane, such as activation of sodium channels to accelerate Na<sup>+</sup> influx, depolarize cell membranes, and enhance the autonomy of fast-acting cells such as atrial conduction tissue and atrioventricular bundle-Purkinje fiber system, increasing Ca<sup>2+</sup> inflow and inhibiting outward K<sup>+</sup> current to prolong repolarization time, increase the incidence of post depolarization, and cause reentry excitation.

In the present study, PDQ pills were chosen as the test drug. PDQ pills were the dosage form with PDQ as drug substance and

effects against CDDP-induced acute nephrotoxicity through the caspase and Sirt1/NF-κB signaling pathway.<sup>17</sup> In addition, PDQ can attenuate isoproterenol-induced myocardial ischemia injury through suppressing the activity of glutathione peroxidase, reducing the superoxide dismutase and increasing the malondialdehyde content.<sup>18</sup> The development of myocardial ischemia injury, along with the structural heart diseases and genetic deficits, has frequently been associated with arrhythmias.<sup>19</sup> Thus, whether PDQ has anti-arrhythmic activity is necessary to be investigated.

<sup>&</sup>quot;School of Pharmaceutical Sciences, Jilin University, Fujin Road 126, Changchun 130021, China. E-mail: wangyijlu03@163.com; Tel: +86-136-1072-9293

<sup>&</sup>lt;sup>b</sup>Department of Hematology and Oncology, The Second Hospital of Jilin University, Changchun 130041, China

<sup>\*\*</sup>College of Basic Medical Sciences, Jilin University, Changchun, 130021, China † Electronic supplementary information (ESI) available. See DOI 10.1039/d0ra01683g

PEG 4000 (Polyethylene Glycol 4000) as excipients with a ratio of 1:3 in mass. We evaluated the anti-arrhythmic effects of PDQ pills on aconitine-induced arrhythmia in rats and investigated its electrophysiological mechanism of action in the cardiomyocytes of rat/guinea pigs *in vitro*.

## 2. Materials and methods

#### 2.1 Chemicals and reagents

PDQ (purity > 98.0%) was provided by the School of Pharmaceutical Sciences of Jilin University (Changchun, China). PDQ pills (the dosage form) were prepared by Jilin Shengya Pharmaceutical Technology Co., Ltd. (Dunhua, China). PEG 4000 was bought from Hunan Erkang Pharmaceutical Co., Ltd. (Hunan, China). Chloral hydrate was purchased from Sinopharm Chemical Reagent Co., Ltd. Aconitine was bought from Hainan Sinochem United Pharmaceutical Industry Co., Ltd. Diltiazem hydrochloride tablets (catalogue number: 1009062, 30 mg per tablet) were purchased from Tianjin Tianbian Pharmaceutical Co., Ltd.

#### 2.2 Animals and administration

2.2.1 Animal. All the animal experiments were conducted based on the guide for the administration of laboratory animals (Directive 86/609/EEC in the Protection of Animals Used for Experimental and Other Scientific Purposes, 1986) and were approved by the Review Committee of Animal Care and Use of Jilin University. Male SPF Wistar rats weighing between 200 g and 220 g were purchased from the Animal Center of Norman Bethune Medical College of Jilin University (production certificate no. SCXK (JI) 2007-0003, SCXK (JI) 2013-0001; using certificate no. SCXK (JI) 2007-0011, SCXK (JI) 2013-0005). All rats had free access to standard laboratory food and water. They were maintained under standardized laboratory conditions (temperature 23  $\pm$  1 °C, relative humidity 50–70%, 12 h light/ dark cycle, with the light cycle beginning at 6:00 a.m., the ambient noise level was lower than 50 dB). In vivo experiment was carried out in rats and the rat ventricular myocytes were separated to investigate ion channel.

Guinea pigs weighing between 300 g and 350 g were purchased from the Animal Center of Norman Bethune Medical College of Jilin University (using certificate no. SCXK (JI) 2013-0005). Ventricular myocytes were separated to investigate action potentials.

2.2.2 Preparation of arrhythmic model and PDQ pills administration. After a week of acclimatization, the rats were randomly divided into seven groups (n=10 per group): (1) normal control group, (2) PEG 4000 group (240 mg kg $^{-1}$ ), (3) aconitine-induced arrhythmic model group, (4) H-PDQ (high dose of PDQ pills, containing PDQ 80 mg kg $^{-1}$ ), (5) M-PDQ (middle dose of PDQ pills, containing PDQ 40 mg kg $^{-1}$ ), (6) L-PDQ (low dose of PDQ pills, containing PDQ 20 mg kg $^{-1}$ ), (7) positive control group (diltiazem hydrochloride, 6 mg kg $^{-1}$ ). The rats of normal and model groups were administrated 0.9% NaCl aqueous solution (5 mL kg $^{-1}$ ). The rats of PEG 4000 group were administrated PEG 4000 (48.0 mg mL $^{-1}$ ). PDQ groups were

administered with PDQ pills aqueous solution (64.0, 32.0,  $16.0 \text{ mg mL}^{-1}$ ), which were grinded and suspended in 0.9% NaCl aqueous solution. The rats of positive drug group were administered with diltiazem hydrochloride aqueous solution (1.2 mg mL<sup>-1</sup>).

The rats in treatment groups were intragastrically administered with PEG 4000, PDQ or diltiazem hydrochloride 4 h before the experiment. Then, rats were anesthetized using 10% chloral hydrate. Aconitine (60 µg kg<sup>-1</sup>, 1 mL kg<sup>-1</sup>) was administrated *via* sublingual vein within 5 seconds, while the rats of normal group were injected with physiological saline.<sup>21</sup> Electrocardiogram was recorded using a Power Lab Multi-channel physiological recorder (Power Lab15T, ML818, AD Instruments Shanghai Trading Co., Ltd., Shanghai, China).

#### 2.3 Action potential (AP) measurement

Normal perfusion condition: the cells were divided into DMSO (0.1%) perfused control group and different concentrations of PDQ (0.2  $\mu$ g mL<sup>-1</sup>, 2.0  $\mu$ g mL<sup>-1</sup>, 20.0  $\mu$ g mL<sup>-1</sup>).

#### 2.4 Solutions preparation

Ca<sup>2+</sup> Tyrode's solution contained (in mM): NaCl 143.0, KCl 5.4, CaCl<sub>2</sub>·2H<sub>2</sub>O 1.8, MgCl<sub>2</sub>·6H<sub>2</sub>O 1.8, NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O 0.25 and HEPES 5.0 (adjusted to pH 7.4 with NaOH). The Ca2+-free Tyrode's solution was prepared by removing CaCl2 from the Tyrode's solution. The extracellular solution contained (in mM): NaCl 115.0, KCl 4.7, MgSO<sub>4</sub> 1.2, CaCl<sub>2</sub>·2H<sub>2</sub>O 2.0, NaHCO<sub>3</sub> 2.5, KH<sub>2</sub>PO<sub>4</sub> 1.2, glucose 10.0, tetrodotoxin (TTX) 20.0, 4-aminopyridine (4-AP) 5.0 (pH 7.4 adjusted with NaOH). The pipette solution for recording  $I_{Ca,L}$  and  $I_{K1}$  (the inward rectifier potassium current) contained (in mM): cesium aspartate 120.0, CsCl 30.0, KH<sub>2</sub>PO<sub>4</sub> 10.0, MgSO<sub>4</sub> 3.0, NaCl 5.0, HEPES 5.0, K<sub>2</sub>ATP 5.0, EGTA 0.1 (pH 7.3 adjusted with CsOH). The pipette solution for recording IK (outward delay rectifier potassium current) contained (in mM): potassium aspartate 80.0, KCl 42.0, KH<sub>2</sub>PO<sub>4</sub> 10.0, Mg<sup>2+</sup>-ATP 10.0, phosphocreatin 3.0, K<sup>+</sup>-EGTA 5.0 (pH 7.2– 7.4 adjusted with KOH). The Kreb's solution used for cell storage contained (in mM): KOH 70.0, L-glutamic acid 50.0, KCl 40.0, taurine 20.0, KH<sub>2</sub>PO<sub>4</sub> 20.0, MgCl<sub>2</sub>·6H<sub>2</sub>O 3.0, glucose 10.0, HEPES 10.0, EGTA 0.5 (pH 7.4 adjusted with KOH).

PDQ was dissolved in 0.1% DMSO, the final concentration was 200  $\mu g$  mL<sup>-1</sup>.

#### 2.5 Myocyte preparation

Wistar rats/adult guinea pigs were anesthetized with sodium phenobarbital (30 mg kg $^{-1}$ , intraperitoneally), and the heart was excised and fixed in a Langendorff apparatus. The Ca $^{2+}$  Tyrode's solution was used to retrograde perfusion in the heart for the first 2 min, then the Ca $^{2+}$ -free Tyrode's solution for 5 min, and at last the enzymatic solution (15 mg collagenase in 100 mL Ca $^{2+}$ -free Tyrode's solution) for 10 min. Afterwards, the ventricular muscle were cut into small pieces (1 mm $^3$ ) and lightly oscillated for 10 min at 37 °C. Ventricular myocytes were filtered through nylon mesh and stored in Krebs solution at 4 °C. The perfusate was bubbled with 95% O $_2$  + 5% CO $_2$  at a flow of 8 mL min $^{-1}$  at 37 °C. Ventricular myocytes from Wistar rats

Paper **RSC Advances** 

were used to measure the L-type calcium currents, while the myocytes of adult guinea pigs were used to measure the action potential of ventricular myocytes and the potassium currents.

#### Whole-cell patch-clamp recording

Isolated single ventricular myocytes were used for the whole-cell recordings. Glass microelectrodes were constructed by a twostage pulling and then the electrode resistance was maintained at 1.0-3.0 M $\Omega$  when filled with the internal electrode solution. L-type calcium currents, and potassium currents were recorded with a CEZ-2400 amplifier (Nihon Kohden, Japan) and linked to a 12 bit analog to digital converter (AD/DA) card (Axon, America) at 3 KHz. pCLAMP 6.03 software (Axon Instruments) was applied to generate voltage clamp protocols and retrieve data. Clampfit 6.02 software (Molecular Devices, America) was used to analyze the current traces.

#### 2.7 Molecular docking of PDQ

To clarify the mode of action of PDQ on  $I_{Ca,L}$  and  $I_{K}$ , a molecular docking study was carried out to measure the relative binding energies and localized binding sites in the active pocket. The study was performed using GLIDE (Grid-based Ligand Docking with Energetics) (GLIDE, version 6.7, Schrödinger, LLC, New York, USA, 2015) software developed by Schrödinger. Maestro Elements (2015-2) was used for all the steps involving protein and ligand preparation, receptor grid generation, and docking. The X-ray crystal structure of calcium channel [Protein Data Bank (PDB) code: 4TMF] and potassium channel (PDB code: 2A79) were retrieved from the PDB database (http:// www.rcsb.org/pdb) according to previous studies.22,23 The Protein Preparation Wizard in the GLIDE software was used to prepare the receptors. The structures of proteins were optimized after a series of processes, including assigning bond orders and water orientations, removing water, adding hydrogen, and creating zero-order bonds to metals and disulphide bonds.24 Two-dimensional structure of PDQ (ligand) were drawn with Maestro Elements (Maestro Elements, 2.2). LigPrep module (2015-2) of Schrödinger Suite was used to generate the three-dimensional structure of PDQ by assigning the bond orders and angles. In addition, the ligand was subjected to minimization using the OPLS3 force field. For GLIDE docking, the prepared structure of calcium channel, potassium channel, and ligand (PDQ) were imported into the workspace using GLIDE v6.7 from Schrödinger Suite.25-27 Extra precision (XP) docking was carried out, and the parameters of scaling factor and partial charge cutoff were set at the default values 0.80 and 0.15, respectively.28 Figures of the docking results were subsequently prepared using PyMOL (Schrödinger).

#### 3. Statistical analysis

All data are expressed as the mean  $\pm$  standard deviation. GraphPad Prism 7.0 software was applied to analyze the data. Data analyses were performed using one way ANOVA. p < 0.05was considered statistically significant.

## Results

## 4.1 PDQ reduced aconitine-induced arrhythmias and mortality in rats in dose-dependent manner

Compared with the normal control group, the significantly elevated incidence rate of VT and VF were 100% and 60% respectively in the aconitine-induced group, suggesting the chemical induced arrhythmic model was successfully established. The PEG 4000 group showed no effect on the model rats. The mortality rate of aconitine-induced group (Model) was 40%, while the mortality rates of low-, medium- and high-doses of PDQ (L-PDQ, M-PDQ and H-PDQ) were 20%, 10%, and 0% respectively (Table 1). In addition, aconitine-induced group showed a significantly shorter survival time (p < 0.01). As for both of the positive control group and H-PDQ group, the survival time were 600 s, which showed significantly difference compared with model group (Fig. 1). Moreover, the H-PDQ showed a significantly decreased arrhythmic incidence and shorter duration time of VT (p < 0.01), which was similar to the positive group (Table 1 and Fig. 2). PDQ reduced aconitine-induced arrhythmias and mortality in rats in dose-dependent manner.

## 4.2 PDQ prolonged APD and reduced APA in ventricular myocytes

PDQ pre-treatment has the tendency of prolonging action potential duration (APD) with the increase of dosage. There is no significant difference for APD at 50% repolarisation (APD<sub>50</sub>) between PDQ treated groups and normal group. However, 2.0 μg  $mL^{-1}$  (p < 0.05) and 20.0 µg  $mL^{-1}$  PDQ (p < 0.01) significantly prolonged the APD at 90% repolarization (APD<sub>90</sub>). In addition, 20.0 μg mL<sup>-1</sup> PDQ remarkably reduced the action potential amplitude (APA) (p < 0.001) versus the control group. The absolute values of resting potential (RP) were significantly reduced by 2.0  $\mu$ g mL<sup>-1</sup> PDQ and 20.0  $\mu$ g mL<sup>-1</sup> PDQ treatment. The results were shown in Table 2. These results suggested that PDQ treatment may probably influence the phase 3 or 4 of APD, but the detail mechanisms need to be investigated.

## 4.3 PDQ reduced L-type calcium peak current in dosedependent pattern

In the normal perfusion condition,  $I_{Ca,L}$  was elicited by a depolarizing pulse to -40 mV from a prepulse of +10 mV (holding potential -50 mV) in ventricular cells. Flip potential was at +50 mV to

Table 1 The mortality rate, VT incidence and VF incidence

Group	Mortality rate (%)	VT incidence (%)	VF incidence (%)	
Normal	0.0	0.0	0.0	
PEG 4000	40.0	100.0	60.0	
Model	$40.0^{\#}$	100.0##	60.0##	
L-PDQ	20.0	100.0	30.0	
M-PDQ	10.0	100.0	10.0*	
H-PDQ	0.0**	90.0	0.0**	
Positive	0.0**	30.0**	20.0	

<sup>&</sup>lt;sup>a</sup> Compared with normal group, p < 0.05, p < 0.01; compared with model group, \*\*p < 0.01.




Fig. 1 Effects of PDQ on survival time of aconitine-induced arrhythmias (compared with normal group,  $^{\#}p$  < 0.05; compared with model group,  $^{**}p$  < 0.01).

+60 mV, the maximum  $I_{\rm Ca,L}$  ( $I_{\rm Ca,L}$ , peak) was  $-3.64 \pm 0.35$  pA pF $^{-1}$ . The current was sensitive to verapamil, indicating that it was L-type Ca $^{2+}$  current. The average maximum  $I_{\rm Ca,L}$  of 0.2, 2.0 and 20.0 µg mL $^{-1}$  PDQ were  $-3.64 \pm 0.34$  pA pF $^{-1}$ ,  $-3.03 \pm 0.27$  pA pF $^{-1}$  (p < 0.05) and  $-2.91 \pm 0.24$  pA pF $^{-1}$  (p < 0.01) vs.  $-3.64 \pm 0.35$  pA pF $^{-1}$  in control group (Fig. 3), indicating that PDQ exerted anti- $I_{\rm Ca,L}$  effect in a dose-dependent manner.

# 4.4 PDQ inhibited delayed rectifier $K^+$ channels $(I_K)$ , not inward rectifier $K^+$ channels $(I_{K1})$

In common condition,  $I_{\rm K}$  was from -50 mV to +50 mV by a prepulse of +10 mV (holding potential -40 mV) in ventricular cells within 400 ms. In the present study,  $I_{\rm K}$  was activated at

-30 mV in the normal group, and the maximum peak outward current was  $16.67 \pm 1.78$  pA pF $^{-1}$  at +50 mV. After adding tetraethylammonium (TEA), the potential amplitude was inhibited, indicating it was  $I_{\rm K}$  current. After perfusion for 3 min using different concentrations of PDQ, the peak current at +50 mV of 0.2, 2.0 and 20.0 µg mL $^{-1}$  PDQ were  $15.63 \pm 0.36$  pA pF $^{-1}$ , 14.63  $\pm 0.92$  pA pF $^{-1}$  (p < 0.05) and 14.15  $\pm 1.12$  pA pF $^{-1}$  (p < 0.05) vs.  $16.67 \pm 1.78$  pA pF $^{-1}$  in control group. Current–voltage curve moved downward, suggesting that PDQ can inhibit  $I_{\rm K}$  in a dose-dependent pattern (Fig. 4).

#### 4.5 PDQ has no effect on $I_{K1}$ in ventricular myocytes

In the normal perfusion condition,  $I_{\rm K1}$  was elicited by a depolarizing pulse to +30 mV from a prepulse of -100 mV (holding potential -40 mV) in 10 mV increments in ventricular cells. Then it reached a steady state, and didn't change over time, showing inward rectification characteristics. Flip potential was about -40 mV, and the maximum  $I_{\rm K1}$  was  $-23.12\pm3.55$  pA pF<sup>-1</sup> at -100 mV. The  $I_{\rm K1}$  of 0.2, 2.0 and 20.0 µg mL<sup>-1</sup> PDQ were  $-22.35\pm3.58$  pA pF<sup>-1</sup>,  $-20.55\pm3.94$  pA pF<sup>-1</sup> and  $-19.71\pm2.80$  pA pF<sup>-1</sup>, which showed no significant difference compared with the normal group, indicating PDQ had no effect on  $I_{\rm K1}$  (Fig. 5).

#### 4.6 Molecular docking for calcium and potassium channel

Molecular docking was used to measure the localized binding sites and relative binding energies in the active pocket. As displayed in Fig. 6A, the model provided the most probable binding sites and structural configurations of PDQ in calcium




Fig. 2 Effects of PDQ on duration time (A) and number of occurrences (B) of ventricular tachycardia (VT) (compared with model group, \*p < 0.05, \*\*p < 0.01).

**Table 2** Effects of PDQ on action potential in rat ventricular myocytes in vitro  $(\pm s)^a$ 

Group	Dose ( $\mu g \ mL^{-1}$ )	APA (mV)	$V_{\text{max}} \left( V \text{ s}^{-1} \right)$	RP (mV)	APD50 (ms)	APD90 (ms)
Normal	_	$107.96 \pm 5.73$	$13.49\pm1.40$	$-82.85 \pm 4.32$	$253.65 \pm 42.23$	$296.52 \pm 39.23$
PDQ-1	0.002	$107.11 \pm 5.71$	$13.87 \pm 1.79$	$-82.44 \pm 5.95$	$251.80 \pm 49.93$	$296.58 \pm 44.97$
PDQ-2	0.02	$108.45 \pm 5.13$	$12.21\pm0.90$	$-82.06 \pm 7.78$	$265.15 \pm 49.52$	$310.88 \pm 41.68$
PDQ-3	0.2	$106.37 \pm 2.02$	$12.97\pm1.56$	$-82.53 \pm 2.63$	$277.57 \pm 48.83$	$327.35 \pm 39.41$
PDQ-4	2.0	$104.39 \pm 10.96$	$13.87\pm2.75$	$-74.07 \pm 3.46**$	$291.77 \pm 47.20$	$346.32 \pm 37.29*$
PDQ-5	20.0	$91.10 \pm 2.48***$	$12.36\pm2.61$	$-69.75 \pm 4.78***$	$315.00 \pm 53.56$	$364.40 \pm 40.74**$

<sup>&</sup>lt;sup>a</sup> Compared with normal group, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

Paper RSC Advances




Fig. 3 Effects of PDQ on current-voltage curve of  $I_{Ca,L}$  in different groups.

channel (4TMF). PDQ formed one hydrogen bond at a distance of 1.9 Å with the residue (GLU-226), and 2.4 Å with the residue (THR-221). Docking calculation predicted three hydrogen bonds forming between PDQ and ASN-158 and ARG-189 of the potassium channel (2A79, Fig. 6B), two hydrogen bond at a distance of 2.3 Å with the residue (ARG-189), and one hydrogen bond with the residue (ASN-158) at a distance of 2.4 Å identified in the binding pocket. This result was consistent with the electrophysiological result for calcium and potassium.

#### Discussion

PDQ belongs to ocotillol type saponogenin, a type that was first found in *Panax quinquefolium*, and is an important and symbolic component of *Panax quinquefolium*. In terms of the complicated effects of ginseng on inotropic and chronotropic effect of the cardiovascular system, it is necessary to clarify the influence of PDQ on different ion channels which are the electrophysiological base for various arrhythmias. In our experiment *in vitro*, PDQ pre-treatment significantly prolonged APD90 in ventricular myocytes of guinea pigs in a concentration-dependent manner, but the APD50 prolongation has no significant difference compared with the normal group. These observations indicated that PDQ may change the ions flow in

phase 2 or 3 which are involved in the  $Ca^{2+}$  and  $K^{+}$  ion influx and efflux cell membrane.

Calcium channels include mainly T type and L type. L-type calcium channels are the most import one for their long duration time, high activation voltage and large conductance.  $I_{Ca,L}$  is the major pathway for facilitating the influx of calcium into cells when cells were excited.  $I_{\text{Ca,L}}$  also plays an important role in cardiac excitability-contraction coupling, the self-discipline of cardiac sinus node and the conduction of atrioventricular node. Nowadays, most calcium channel blockers are targeted at  $I_{Ca,L}$ . In this study, the potential was set at -40 mV, thus it can not only exclude the interference from T-type calcium channels but also avoiding the effects of sodium current. K+ was used instead of Ca2+, resulting in block of the potassium current in cardiomyocytes. There was almost no current depletion because data was collected within 10 min, which guaranteed the reliability of results. 2.0 μg mL<sup>-1</sup> PDQ and 20.0 μg mL<sup>-1</sup> PDQ inhibited I<sub>Ca,L</sub> under different membrane potentials, indicating that PDQ suppressed voltage-dependent ICaL, which may result in the prolonged APD. IK participated in the repolarization process of AP, which played an important role in regulating both




Fig. 4 Effects of PDQ on current-voltage curve of  $I_{\rm K}$ .




Fig. 5 Effects of PDQ on current-voltage curve of  $I_{K1}$ .




Fig. 6 Docked poses of PDQ in 4TMF (A) and 2A79 (B)

the termination of action potential in 2-phase plateau and 3-phase repolarization. The inhibition of  $I_{\rm K}$  by PDQ in dose-independent manner suggested  $I_{\rm K}$  was the major current for prolonging APD. Moreover, PDQ had no effect on  $I_{\rm K1}$ , which was closely relevant for RP. In a word, PDQ may exerted anti-arrhythmic effect by inhibiting  $I_{\rm Ca,L}$  and  $I_{\rm K}$  together. The molecular docking study also verified that PDQ has the relative binding energies and localized binding sites for calcium channel and potassium channel, which was consistent with the results of the animal experiment. Moreover, RP is important for maintaining the excitability of ventricular myocytes. The reduced RP by 2.0  $\mu \rm g$  mL<sup>-1</sup> PDQ and 20.0  $\mu \rm g$  mL<sup>-1</sup> PDQ treatment shortened the distance from the threshold potential, so the excitability of ventricular myocytes was elevated considering the stable  $V_{\rm max}$ .

Aconitine can lead to excitation of cardiac vagus nerve, which can reduce the autonomy of sinoatrial node, excite the ectopic rhythm point in the ventricle, and lead to multiple reentry in the process of cardiac repolarization. Many studies have reported that aconitine had non-selectivity for Na<sup>+</sup>, Ca<sup>2+</sup> and K<sup>+</sup> ion channel. Therefore, PDQ anti-arrhythmic effect by aconitine-induced in rats is likely the integrated effect resulting from improved cardiac repolarization of Ca<sup>2+</sup> and K<sup>+</sup>. The prolongation of APD is the main reason for terminating reentrant arrhythmias.

Owing to that APD was regulated by multiple ion channels in membrane.  $I_{\text{Ca,L}}$  current was critical to the depolarization and repolarization of AP while  $I_{\text{K}}$  was the major current in phase 3 of repolarization. Therefore, the APD and the effective refractory period were regulated by  $I_{\text{Ca,L}}$  and  $I_{\text{K}}$  together. In addition,  $I_{\text{K1}}$ , the dominant current of RP, can affect the excitability of ventricular myocytes by regulating RP. In terms of electrophysiology,  $I_{\text{Ca,L}}$  and  $I_{\text{K}}$  changes seem to be more important in revealing the mechanisms of anti-arrhythmic effect of PDQ.

#### Author contributions

Investigation, Writing-original draft, L. J.; Software, C. W.; Methodology, X. C. & J. Li.; Conceptualization, Y. W.; Funding acquisition, P. L.; Writing-review and editing, J. Liu.

## **Fundings**

This research was supported by the Science and Technology Development Plan of Jilin Province (No. 201603033YY) and Key Technologies Research and Development Program (No. 2017YFC1702105).

## Conflicts of interest

The authors declare that they have no conflict of interest concerning this article.

## References

- 1 B. DePiccoli, F. Rigo, A. Raviele, E. Piccolo, C. Maggiolo, A. Milanesi and M. Simone, Transesophageal echocardiographic evaluation of the morphologic and hemodynamic cardiac changes during ventricular fibrillation, *J. Am. Soc. Echocardiogr.*, 1996, **9**, 71–78.
- 2 S. B. S. Erin, H. P. D. Brent, J. M. D. Eric, H. M. D. Paul and M. P. D. Robert, Defibrillation Causes Immediate Cardiac Dilation in Humans, *J. Cardiovasc. Electrophysiol.*, 2010, 14, 832–836.
- 3 R. A. Berg, V. L. Sorrell, K. B. Kern, R. W. Hilwig, M. I. Altbach, M. M. Hayes, K. A. Bates and G. A. Ewy, Magnetic resonance imaging during untreated ventricular fibrillation reveals prompt right ventricular overdistention without left ventricular volume loss, *Circulation*, 2005, 111, 1136–1140.
- 4 J. A. Lima, J. L. Weiss, P. A. Guzman, M. L. Weisfeldt, P. R. Reid and T. A. Traill, Incomplete filling and incoordinate contraction as mechanisms of hypotension during ventricular tachycardia in man, *Circulation*, 1983, 68, 928.
- 5 T. Hachenberg, D. Hammel, T. Mollhoff, T. Brussel, M. Block, M. Borggrefe, H. Haberecht, H. H. Scheld and M. Wendt, Cardiopulmonary effects of internal cardioverter/defibrillator implantation, *Acta Anaesthesiol.* Scand., 2010, 35, 626–630.

- 6 G. Y. Yeh, R. B. Davis and R. S. Phillips, Use of Complementary Therapies in Patients With Cardiovascular Disease, *Am. J. Cardiol.*, 2006, **98**, 673–680.
- 7 C. Pharand, M. L. Ackman, C. A. Jackevicius, F. L. Paradiso-Hardy and G. J. Pearson, Use of OTC and Herbal Products in Patients with Cardiovascular Disease, *Ann. Pharmacother.*, 2003, 37, 899–904.
- 8 L. J. Harnack, S. A. Rydell and J. Stang, Prevalence of Use of Herbal Products by Adults in the Minneapolis/St Paul, Minn, Metropolitan Area, *Mayo Clin. Proc.*, 2001, **76**, 688–694.
- 9 J. H. Kim, Cardiovascular Diseases and Panax ginseng: A Review on Molecular Mechanisms and Medical Applications, *J. Ginseng Res.*, 2012, (1), 16–26.
- 10 Z. Y. Tang, T. T. Tian, L. Fu, Y. Y. Tang, Y. Y. Xiang, H. B. Fan and Y. Lin, Effects of ginseng stem and leaf saponinson on electrocardiographic changes and death time in mice, *Lab. Anim. Sci.*, 2009, **26**, 4–7.
- 11 T. T. Nguyen, K. Matsumoto, K. Yamasaki and H. Watanabe, Majonoside-R2 reverses social isolation stress-induced decrease in pentobarbital sleep in mice: possible involvement of neuroactive steroids, *Life Sci.*, 1997, 61, 395.
- 12 S. Y. Lee, J. J. Jeong, T. H. V. Le, S. H. Eun, M. D. Nguyen, J. H. Park and D. H. Kim, Ocotillol, a Majonoside R2 Metabolite, Ameliorates 2,4,6-Trinitrobenzene-sulfonic Acid-Induced Colitis in Mice by Restoring the Balance of Th17/Treg Cells, *J. Agric. Food Chem.*, 2015, 63, 7024–7031.
- 13 Z. Zhou, C. Ma, H. Zhang, Y. Bi, X. Chen, H. Tian, X. Xie, Q. Meng, P. J. Lewis and J. Xu, Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents, *Eur. J. Med. Chem.*, 2013, 68, 444–453.
- 14 Q. L. Tran, I. K. Adnyana, Y. Tezuka, T. Nagaoka and S. Kadota, Triterpene Saponins from Vietnamese Ginseng (Panax vietnamensis) and Their Hepatocyto-protective Activity, J. Nat. Prod., 2001, 64, 456–461.
- 15 P. Y. Li and J. P. Liu, The semisynthesis method and drug use of Pseudo-ginsengenin DQ, *China Pat.*, CN200510016774.4, 2009.
- 16 Q. W. Ren, G. Q. Yang, M. Q. Guo, Y. Li, H. H. Tang, Y. Li, X. J. Fang, Y. X. Sun, J. G. Qi, J. W. Tian and H. B. Wang, Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance, *Eur. J. Med. Chem.*, 2018, 161, 118–130.
- 17 Z. Qi, Z. Li, W. Li, Y. H. Liu, C. Z. Wang, H. Q. Lin, J. P. Liu and P. Y. Li, Pseudoginsengenin DQ Exhibits Therapeutic Effects in Cisplatin-Induced Acute Kidney Injury via Sirt1/NF-κB and Caspase Signaling Pathway without Compromising Its Antitumor Activity in Mice, *Molecules*, 2018, 23, 3038.
- 18 T. Wang, Q. Meng, J. Zhang, Y. Bi and N. Jiang, Study on the structure-function relationship of 20(s)-panaxadiol and its

- epimeric derivatives in myocardial injury induced by isoproterenol, *Fitoterapia*, 2010, **81**, 783–787.
- 19 Z. P. Cao, Y. Zhang, L. Mi, X. Y. Luo, M. H. Tian and B. L. Zhu, The Expression of B-Type Natriuretic Peptide After CaCl<sub>2</sub>-Induced Arrhythmias in Rats, *Am. J. Forensic Med. Pathol*, 2016, 37, 1.
- 20 M. S. Amran, K. Hashimoto and N. Homma, Effects of sodium-calcium exchange inhibitors, KB-R7943 and SEA0400, on aconitine-induced arrhythmias in guinea pigs in vivo, in vitro, and in computer simulation studies, J. Pharmacol. Exp. Ther., 2004, 310, 83–89.
- 21 J. S. Lou, H. Wu, L. F. Wang, L. Zhao, X. Li, Y. Kang, K. Wen and Y. Q. Yin, Taurine-magnesium coordination compound, a potential anti-arrhythmic complex, improves aconitine-induced arrhythmias through regulation of multiple ion channels, *Toxicol. Appl. Pharmacol.*, 2018, 356, 182–190.
- 22 L. Sadeghi, R. Yekta and G. Dehghan, New mechanisms of phenytoin in calcium homeostasis: competitive inhibition of CD38 in hippocampal cells, *Daru, J. Pharm. Sci.*, 2018, 26, 191–198.
- 23 M. H. Park, S. H. Lee, D. H. Chu, K. H. Won, B. H. Choi, H. Choe and S. H. Jo, Effect of Azelastine on Cardiac Repolarization of Guinea-Pig Cardiomyocytes, hERG K+Channel, and Human L-type and T-type Ca<sup>2+</sup> Channel, *J. Pharmacol. Sci.*, 2013, **123**, 67–77.
- 24 N. Q. Zhang, C. Z. Wang, Z. Z. Wang, Z. Li, J. Y. Sai, Y. Meng, F. Wang, P. Y. Li and J. H. Liu, Anti-myocardial ischaemic effect of pseudoginsenoside F11 by inhibiting expression of beta1-adrenoceptor in rats with coronary artery ligation, *J. Funct. Foods*, 2017, 36, 224–232.
- 25 R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis and P. S. Shenkin, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem., 2004, 47, 1739–1749.
- 26 R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin and D. T. Mainz, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, *J. Med. Chem.*, 2006, 49, 6177– 6196.
- 27 T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, *J. Med. Chem.*, 2004, 47, 1750–1759.
- 28 L. Xiong, Z. Qi, B. Zheng, Z. Li, F. Wang, J. Liu and P. Li, Inhibitory effect of triterpenoids from *panax* ginseng on coagulation factor X, *Molecules*, 2017, 22, 649.